Point32Health reported an adjusted net income of $63 million in the third quarter on $2.3 billion in revenue, crediting tighter operations and stronger management of medical and pharmaceutical costs.
The quarter included $40 million in operating income and $23 million in investment income.
“While we remain confident in the continued progress we are experiencing, the seasonality of the fourth quarter can create volatility in utilization and cost trends,” CFO Michael Marrone said Nov. 16.
For the first nine months of 2026, adjusted net income at the company was $379 million on $7 billion in revenue (2.4% operating margin), compared with $4 million in adjusted net income and a -1.5% operating margin in the same period of 2025. The nine-month results include a gain from the sale of its former subsidiary Integra Partners.
In 2025, Point32Health posted a $301 million operating loss and cut more than 460 jobs.
